Literature DB >> 12869833

Role of Baseline pol Genotype in HIV-1 Fitness Evolution.

Jan Weber1, Hector R Rangel, Bikram Chakraborty, Michael L Marotta, Hernan Valdez, Katrien Fransen, Eric Florence, Elizabeth Connick, Kimberly Y Smith, Robert L Colebunders, Alan Landay, Daniel R Kuritzkes, Michael M Lederman, Guido Vanham, Miguel E Quiñones-Mateu.   

Abstract

Viral fitness can be modified upon development of antiretroviral drug resistance, usually by selection of compensatory mutations. In this study, we have used HIV-1 isolates from individuals receiving a protease inhibitor (PI)-based regimen to analyze the impact of basal genetic background on viral fitness evolution. Paired plasma samples and HIV-1 isolates were obtained from 10 PI-naive HIV-infected individuals enrolled in 2 different studies of combination antiretroviral therapy. Genomic regions from pol and env were sequenced. Viral fitness was measured using growth competition experiments followed by heteroduplex tracking analysis. Baseline genotypic analyses of pol showed that 9 of 10 viruses had a different degree of secondary mutations in the protease gene at codons associated with PI resistance (i.e., 10I, 36I, 63P, 71T, and 77I). After 48 weeks of PI-based therapy, a strong correlation was observed between protease genetic divergence and viral fitness difference (r = 0.78, P = 0.03), but not with reverse transcription or Env divergence, suggesting that genotypic changes in the protease gene were driving HIV-1 evolution in these patients. As expected, an inverse correlation was observed between the number of protease and reverse transcription primary mutations and viral fitness (r = -0.65, P < 0.0001). However, our results suggest that the preexistence of secondary mutations in protease genetic background may have implications in HIV-1 fitness evolution and virologic response to antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12869833     DOI: 10.1097/00126334-200308010-00005

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  5 in total

1.  Commentary on the role of treatment-related HIV compensatory mutations on increasing virulence: new discoveries twenty years since the clinical testing of protease inhibitors to block HIV-1 replication.

Authors:  Eric J Arts
Journal:  BMC Med       Date:  2012-10-03       Impact factor: 8.775

2.  Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.

Authors:  Jan Weber; Bikram Chakraborty; Jitka Weberova; Michael D Miller; Miguel E Quiñones-Mateu
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

3.  Diversity of human immunodeficiency virus type 1 subtype A and CRF03_AB protease in Eastern Europe: selection of the V77I variant and its rapid spread in injecting drug user populations.

Authors:  Nikita I Roudinskii; Anna L Sukhanova; Elena V Kazennova; Jonathan N Weber; Vadim V Pokrovsky; Vladimir M Mikhailovich; Aleksei F Bobkov
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

4.  Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors.

Authors:  Jan Weber; Justine D Rose; Ana C Vazquez; Dane Winner; Nicolas Margot; Damian J McColl; Michael D Miller; Miguel E Quiñones-Mateu
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

5.  Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus.

Authors:  Rika Draenert; Todd M Allen; Yang Liu; Terri Wrin; Colombe Chappey; Cori L Verrill; Guillem Sirera; Robert L Eldridge; Matthew P Lahaie; Lidia Ruiz; Bonaventura Clotet; Christos J Petropoulos; Bruce D Walker; Javier Martinez-Picado
Journal:  J Exp Med       Date:  2006-03-13       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.